Hormonal
Carriers of the preproghrelin Leu72Met polymorphism (specifically Met72 allele) exhibit lower body mass index, fat mass, and visceral adiposity compared to non-carriers, suggesting a protective effect against obesity.
If you have the Met72 variant, your body may naturally resist fat accumulation better than others. However, since this is a rare genetic variant, most people should focus on standard evidence-based weight management: caloric balance and physical activity. This finding highlights that individual biological responses to energy balance vary significantly.
The preproghrelin Met72 carrier status seems to be protective against fat accumulation and associated metabolic comorbidities.
Why this rating
The study uses large cohorts (n=3004) and multiple phenotypic measures, but the associations are specific to certain ethnicities and genotypes, and the mechanism is speculative.
Source
Role of Ghrelin Polymorphisms in Obesity Based on Three Different Studies
Olavi Ukkola et al. · Obesity Research · 2002
DOI 10.1038/oby.2002.106
More from this paper
- The Arg51Gln mutation in the ghrelin gene is associated with significantly lower plasma ghrelin concentrations, but this reduction does not translate to a protective effect against obesity or altered obesity-related phenotypes.Moderate
- Met72 allele carriers, particularly women, exhibit a lower prevalence of hypertension compared to non-carriers, suggesting a protective effect against cardiovascular comorbidities associated with obesity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →